Profile data is unavailable for this security.
About the company
Virbac SA is a France-based veterinarian pharmaceutical company that specializes in the development and production of vaccines and medicines for domestic animals and livestock. Its production centers are located in France, Australia, the United States, Mexico, Vietnam, Brazil and South Africa. Its development efforts focus mainly on formulating drugs designed to prevent or cure certain animal diseases. Its product portfolio encompasses pet medications such as pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds and rodents, as well as livestock medications including pest control drugs and antibiotics intended for cattle, sheep, pigs and poultry. It also offers food and electronic identification chips for pets.
- Revenue in EUR (TTM)1.43bn
- Net income in EUR133.03m
- Incorporated1984
- Employees5.62k
- LocationVirbac SA13e rue LID - BP 27CARROS 06511FranceFRA
- Phone+33 492087100
- Fax+33 492087165
- Websitehttps://corporate.virbac.com/
More ▼
Mergers & acquisitions
| Acquired company | VIRP:PAR since announced | Transaction value |
|---|---|---|
| Norbrook Licences Ltd | 7.10% | 133.73m |
Data delayed at least 15 minutes, as of Feb 17 2026 14:40 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhejiang Huahai Pharmaceutical Co., Ltd. | 1.06bn | 57.17m | 2.87bn | 9.07k | 48.25 | 2.47 | -- | 2.70 | 0.3256 | 0.3256 | 6.00 | 6.35 | 0.4279 | 0.9611 | 3.17 | 960,689.80 | 2.18 | 5.67 | 3.15 | 7.93 | 59.76 | 60.79 | 5.10 | 11.66 | 0.7399 | 8.95 | 0.4519 | 31.74 | 14.91 | 12.12 | 34.74 | 14.46 | 18.47 | 6.58 |
| Grand Pharmaceutical Group Ltd | 1.26bn | 224.51m | 2.89bn | 12.44k | 12.70 | 1.54 | 10.34 | 2.29 | 0.5943 | 0.5943 | 3.35 | 4.90 | 0.4557 | 3.66 | 3.88 | 976,472.80 | 7.99 | 10.40 | 10.81 | 14.24 | 57.64 | 61.04 | 17.53 | 22.80 | 0.9872 | -- | 0.2107 | 29.12 | 10.59 | 12.06 | 31.30 | 16.49 | 0.7398 | 22.05 |
| Aspen Pharmacare Holdings Ltd | 2.29bn | -57.18m | 2.90bn | 9.13k | -- | 0.6433 | 54.56 | 1.27 | -2.44 | -2.44 | 97.66 | 191.19 | 0.3154 | 1.35 | 3.34 | 4,750,548.00 | -0.7878 | 3.15 | -0.929 | 3.94 | 44.11 | 45.63 | -2.50 | 9.67 | 1.18 | 5.04 | 0.2985 | 33.78 | -3.00 | 5.20 | -124.59 | -- | 13.45 | -- |
| Kiniksa Pharmaceuticals Internationl PLC | 504.58m | 30.31m | 2.90bn | 315.00 | 101.19 | 6.39 | 91.94 | 5.75 | 0.4484 | 0.4484 | 7.81 | 7.10 | 0.9435 | 2.13 | 15.61 | 1,898,327.00 | 5.67 | -8.31 | 6.85 | -9.52 | 87.52 | -- | 6.01 | -17.33 | 3.51 | -- | 0.00 | -- | 56.60 | -- | -406.68 | -- | -38.71 | -- |
| Almirall SA | 1.08bn | 42.14m | 2.90bn | 2.08k | 68.74 | 1.97 | 41.22 | 2.69 | 0.1967 | 0.1967 | 5.00 | 6.87 | 0.4626 | 1.35 | 7.02 | 532,457.60 | 1.81 | 0.0824 | 2.06 | 0.0971 | 77.61 | 78.13 | 3.91 | 0.2141 | 1.93 | -- | 0.186 | -- | 10.20 | 2.88 | 126.37 | -37.44 | 3.63 | -- |
| J B Chemicals and Pharmaceuticals Ltd | 389.75m | 70.07m | 2.95bn | 5.52k | 41.71 | -- | 34.06 | 7.58 | 47.44 | 47.44 | 263.86 | -- | -- | -- | -- | 7,600,215.00 | -- | 15.91 | -- | 19.18 | 67.95 | 62.00 | 17.98 | 16.36 | -- | 164.76 | -- | 33.55 | 12.45 | 17.16 | 19.35 | 19.53 | 10.52 | 23.03 |
| Camurus AB | 213.62m | 69.36m | 2.97bn | 285.00 | 42.89 | 7.43 | 41.37 | 13.89 | 12.25 | 12.25 | 37.75 | 70.73 | 0.5332 | 1.24 | 5.36 | 7,948,695.00 | 17.31 | 14.26 | 19.13 | 16.65 | 93.11 | 91.95 | 32.47 | 21.07 | 11.78 | -- | 0.0244 | 0.00 | 21.30 | 46.47 | 71.70 | -- | 110.82 | -- |
| Virbac SA | 1.43bn | 133.03m | 3.02bn | 5.62k | 22.64 | 2.83 | 15.49 | 2.11 | 15.88 | 15.88 | 171.01 | 127.13 | 0.7934 | 1.19 | 6.42 | 254,932.90 | 7.36 | 9.61 | 10.03 | 13.56 | 66.54 | 65.89 | 9.28 | 10.96 | 1.04 | 16.57 | 0.2337 | 8.06 | 12.07 | 8.29 | 19.78 | 23.03 | 28.46 | -- |
| Santen Pharmaceutical Co Ltd | 1.58bn | 168.18m | 3.03bn | 3.85k | 18.61 | 1.94 | 11.33 | 1.92 | 92.03 | 92.03 | 865.27 | 880.97 | 0.7205 | 2.26 | 4.18 | 74,823,070.00 | 7.63 | 3.94 | 9.43 | 4.93 | 56.89 | 58.97 | 10.59 | 6.01 | 1.89 | -- | 0.1757 | 71.86 | -0.6494 | 4.43 | 36.09 | 8.94 | 3.61 | 5.92 |
| Suzhou Zelgen Biopharmaceuticals Co Ltd | 90.66m | -16.29m | 3.05bn | 910.00 | -- | 21.75 | -- | 33.67 | -0.5038 | -0.5038 | 2.80 | 4.34 | 0.2482 | 0.446 | 4.77 | 815,689.40 | -4.56 | -17.15 | -8.23 | -25.89 | 89.95 | 93.14 | -18.36 | -118.33 | 1.72 | -- | 0.4949 | -- | 37.91 | -- | 50.52 | -- | 44.66 | -- |
| Ligand Pharmaceuticals Inc | 211.99m | 40.99m | 3.05bn | 68.00 | 88.47 | 3.80 | 43.70 | 14.40 | 2.08 | 2.08 | 12.77 | 48.34 | 0.2066 | 1.01 | 5.47 | 3,694,603.00 | 4.00 | 1.82 | 4.09 | 1.92 | 94.27 | 82.57 | 19.34 | 10.30 | 24.30 | -- | 0.3192 | 0.00 | 27.28 | 6.80 | -107.49 | -- | -6.53 | -- |
| Hubei Jumpcan Pharmaceutical Co Ltd | 750.39m | 201.67m | 3.06bn | 5.03k | 15.11 | 1.81 | -- | 4.08 | 1.80 | 1.80 | 6.69 | 15.02 | 0.3543 | 2.99 | 3.59 | 1,222,407.00 | 9.53 | 15.19 | 11.67 | 19.57 | 75.44 | 81.73 | 26.91 | 26.02 | 5.18 | -- | 0.0437 | 46.90 | -16.96 | 2.93 | -10.32 | 9.30 | -20.43 | 11.19 |
| China Resources Pharmaceutical Group Ltd | 31.87bn | 344.85m | 3.11bn | 86.00k | 9.03 | 0.5101 | 2.21 | 0.0977 | 0.5084 | 0.5084 | 46.99 | 9.00 | 0.9434 | 5.57 | 2.41 | 4,060,622.00 | 2.86 | 3.14 | 10.28 | 11.78 | 15.81 | 15.59 | 3.03 | 3.02 | 1.12 | 11.26 | 0.4248 | 22.38 | 5.30 | 7.41 | -13.06 | 2.95 | 12.42 | 7.30 |
| Kangmei Pharmaceutical Co Ltd | 644.30m | 2.03m | 3.19bn | 4.23k | 1,643.48 | 3.64 | -- | 4.95 | 0.0012 | 0.0012 | 0.3973 | 0.5197 | 0.3785 | 1.64 | 2.23 | 1,246,204.00 | 0.1368 | -21.82 | 0.2232 | -42.17 | 17.12 | -92.73 | 0.3614 | -108.18 | 0.7875 | -- | 0.0162 | -- | 6.47 | -14.63 | -91.64 | -- | -33.46 | -- |
Data as of Feb 17 2026. Currency figures normalised to Virbac SA's reporting currency: Euro EUR
13.05%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Feb 2026 | 160.08k | 1.91% |
| T. Rowe Price Hong Kong Ltd.as of 31 Dec 2025 | 124.64k | 1.49% |
| Threadneedle Asset Management Ltd.as of 31 Jan 2026 | 119.60k | 1.43% |
| Amundi Asset Management SASU (Investment Management)as of 02 Feb 2026 | 115.52k | 1.38% |
| Financi�re de l'�chiquier SAas of 30 Jan 2026 | 109.95k | 1.31% |
| Grandeur Peak Global Advisors LLCas of 31 Oct 2025 | 106.52k | 1.27% |
| Oddo BHF Asset Management SASas of 30 Jan 2026 | 100.46k | 1.20% |
| Lazard Fr�res Gestion SASas of 31 Dec 2025 | 97.80k | 1.17% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 91.12k | 1.09% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 69.06k | 0.82% |
More ▼
Data from 30 Sep 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
